Volume 11, Number 3—March 2005
Dispatch
Inquilinus limosus in Patients with Cystic Fibrosis, Germany
Nele Wellinghausen*
, Andreas Essig*, and Olaf Sommerburg*
, Andreas Essig*, and Olaf Sommerburg*
Table
Antimicrobial susceptibility of Inquilinus limosus strains
| Antimicrobial agent | MIC (µg/mL) | ||||
|---|---|---|---|---|---|
| Isolate A-1 | Isolate A-2 | Isolate A-3 | Isolate B | LMG 20952T | |
| Trimethoprim/sulfamethoxazole | >32 | >32 | >32 | >32 | >32 |
| Amikacin | 8 | 32 | 32 | >256 | >256 |
| Gentamicin | 8 | 16 | 12 | >256 | 12 |
| Tobramycin | >256 | >256 | >256 | >256 | >256 |
| Ampicillin | >256 | >256 | >256 | >256 | >256 |
| Piperacillin/tazobactam | >256 | >256 | >256 | >256 | >256 |
| Cefotaxime | >32 | >32 | >32 | >32 | >32 |
| Ceftazidime | 4 | 4 | 4 | 0.5 | 32 |
| Imipenem | 0.012 | 0.012 | 0.016 | 0.006 | 0.016 |
| Ciprofloxacin | 0.032 | 0.032 | 0.032 | 0.500 | 0.064 |
| Colistin* | Resistant | Resistant | Resistant | Resistant | Resistant |
*Susceptibility testing done by disk diffusion (see text); no zone of inhibition was seen.
Page created: April 25, 2012
Page updated: April 25, 2012
Page reviewed: April 25, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.